Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 18/20 | 0.44 |
| ▸ | ATXN2 | Q99700 | 13/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118538 | 0.93 | ENPP2 (0.48) | ENPP2ATXN2DGAT2MEN1ALDH1A1 | |
| SCHEMBL118448 | 0.92 | ENPP2 (0.43) | ENPP2ATXN2DGAT2MEN1ALDH1A1 | |
| SCHEMBL118406 | 0.92 | ENPP2 (0.45) | ENPP2ATXN2DGAT2 | |
| SCHEMBL117072 | 0.89 | ENPP2 (0.49) | ENPP2ATXN2 | |
| SCHEMBL118575 | 0.88 | ENPP2 (0.49) | ENPP2ATXN2DGAT2 | |
| SCHEMBL118434 | 0.88 | ENPP2 (0.49) | ENPP2ATXN2DGAT2 | |
| SCHEMBL118530 | 0.88 | ENPP2 (0.43) | ENPP2ATXN2DGAT2MEN1ALDH1A1 | |
| SCHEMBL118521 | 0.87 | ENPP2 (0.40) | ENPP2ATXN2DGAT2MEN1ALDH1A1 | |
| SCHEMBL16252474 | 0.87 | ENPP2 (0.40) | ENPP2ATXN2DGAT2MEN1ALDH1A1 | |
| SCHEMBL118740 | 0.87 | ENPP2 (0.48) | ENPP2ATXN2DGAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2414330-B1 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-05-01 | — | — | EP | claimed |
| US-9452997-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-9452997-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-9452997-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2016-09-27 | — | — | US | disclosed |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GMBH (DE) | 2014-11-20 | — | — | US | disclosed |
| US-8822476-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822476-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-8822476-B2 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| EP-2626072-A1 | Piperidine and piperazine derivatives as autotaxin inhibitors | Merck Patent GmbH (DE) | 2013-08-14 | — | — | EP | disclosed |
| EP-2623101-A1 | Piperidine and piperazine derivatives as autotaxin inhibitors | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| EP-2623491-A2 | Piperidine and piperazine derivatives as autotaxin inhibitors | Merck Patent GmbH (DE) | 2013-08-07 | — | — | EP | disclosed |
| EP-2414330-B1 | Piperidine and piperazine derivatives as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140343075-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, PLA2G2E | ENPP2 1/4885ATXN2 1876/4885DGAT2 1926/4885 |
| US-20120059016-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS AUTOTAXIN INHIBITORS | ENPP2, PLA2G12A, PLA2G2E | ENPP2 1/4885ATXN2 1876/4885DGAT2 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.